Stock 600671 HANGZHOU TIANMUSHAN PHARMACEUTICAL ENTERPRISE CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Equities

600671

CNE000000BF3

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
8.89 CNY +4.59% Intraday chart for Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd +11.82% -23.76%
Apr. 26 Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 15 Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Qingdao Yuanjia Medical Treatment Technology proposal of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise was approved.
CI
On October 19, 2023 Qingdao Yuanjia Medical Treatment Technology propose of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise.
CI
TianMuShan Pharma Elects Chairman
MT
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. completed the acquisition of 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.
CI
Qingdao Huilong Huaze Investment Co., Ltd. completed the acquisition of 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd.
CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
TianMuShan Pharmaceutical CFO Steps Down
MT
Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million.
CI
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million.
CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd announced that it expects to receive CNY 278.385575 million in funding from Qingdao Huilong Huaze Investment Co., Ltd.
CI
Yongxin Huarui Proposes Board and Supervisory Board Nominations for Hangzhou Tianmushan's Board
CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Auditor Raises 'Going Concern' Doubt
CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600671 Stock
  4. News Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd